Headache and Migraine

Neurology News Network for the week ending April 4, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 3, 2020.

What happens to the approximately 24% of pediatric patients with migraine who do not respond to the preventive treatments recommended in the AAN guidelines?

The PROMISE-2 clinical trial data suggest that the recently approved, IV-administered eptinezumab (Vyepti; Lundbeck) is effective in both 100- and 300-mg doses for patients with chronic migraine.

Mayo Clinic is in the forefront of changing practice techniques during the COVID-19 pandemic by using video appointments to reach patients.

NeurologyLive’s parent company, MJH Life Sciences, will be hosting the virtual MJH Life Sciences Sleeves Up Blood Drive from March 31 through April 30.

Researchers noted at least a 50% reduction from baseline in mean number of moderate to severe migraine days per month in 48% of the rimegepant group.

After meeting co-primary end points of pain freedom and freedom from the most bothersome symptom, the acute migraine agent has been cleared for a phase 3 trial by the FDA.

"Mind Moments," a podcast from NeurologyLive, brings you exclusive interviews with Barry A. Singer, MD, and Nina Riggins, MD, PhD.

Eton Pharmaceuticals plans to submit a new drug application for ET-101 in the third quarter of 2020, anticipating its formulation to be the first approved oral topiramate solution.

The webinar, a partnership between Women Neurologist's Group (WNG) and NeurologyLive, features the latest updates from CMS on billing and coding for telemedicine visits.

Patients opted for nontriptan acute medications such as opioids and nonsteroidal anti-inflammatory drugs instead of staying on triptans at 12- and 24-month follow-ups.

As neurologists and other specialists may increasingly be called upon to serve as general hospitalists in the wake of the COVID-19 pandemic, keeping health care workers healthy becomes paramount.

The oral calcitonin gene-related peptide receptor antagonist was approved in late February and comes in 8-tablet packs for treatment of 8 migraine attacks with a single, 75-mg dose.

Neurology News Network for the week ending March 14, 2020.

Our patients have a huge need for access to specialists, yet unfortunately, there is a huge shortage of headache specialists.

A proof‐of‐concept assessment showed that women with chronic migraine and insomnia can be reasonably treated with digital cognitive behavioral therapy for insomnia, with data suggesting it may improve both conditions.

The report suggests with moderate certainty that all 3 therapies offer a small or substantial net health benefit and with a high certainty of at least a small net health benefit.

Neurology News Network for the week ending March 7, 2020.

The drug’s Prescription Drug User Fee Act date is set for October 20, 2020.

NeurologyLive's editor in chief Stephen D. Silberstein, MD, discussed the ways to optimizing patient care.

Neurology News Network for the week ending February 29, 2020.

Rimegepant, the only orally disintegrating anti-CGRP tablet, marketed as Nurtec ODT, will be available in a 75-mg dose.

Eptinezumab, Lundbeck’s intravenous monoclonal antibody that will be marketed as Vyepti, will become available for prescription in April 2020 with a recommended dose of 100 mg quarterly.

Two new classes of medications have quickly expanded the pool of available treatment options for patients with migraine, who now have more power than ever to choose the treatment that fits them best.